Vir Biotechnology：扩大肝炎管道和预计 COVID-19收入

StephenW

Vir Biotechnology：扩大肝炎管道和预计 COVID-19收入
2022 年 5 月 2 日 3:42 PM ETVir Biotechnology, Inc. (VIR)GILD、GLAXF、GSK 1 条评论2 赞
概括

     Vir Biotechnology 在 2021 年获得了约 9.172 亿美元的 sotrovimab 合作收入； 预计到 2022 年上半年交付所有剂量的收入约为 11 亿美元。
     在服用 VIR-2218 加 PEG-IFN-a 的患者中，约 95% 的患者达到了 < 100 IU/mL 的乙型肝炎表面抗原 ((HBsAg)) 水平。
     扩大管道，以针对肝炎 Delta 病毒为目标，对 VIR-2218 和 VIR-3434 进行测试。
     预计到 2030 年，全球乙型肝炎病毒市场将达到 356.3 亿美元。
     在一项 2 期研究中，VIR-2218 和 VIR-3434 的组合也正在测试用于治疗乙型肝炎患者； 这项研究的结果预计将在 2023 年下半年发布。

StephenW

Vir Biotechnology: Expanded Hepatitis Pipeline And COVID-19 Revenue Expected
May 02, 2022 3:42 PM ETVir Biotechnology, Inc. (VIR)GILD, GLAXF, GSK1 Comment2 Likes
Summary

    Vir Biotechnology had obtained about $917.2 million of sotrovimab collaboration revenue in 2021; Expects about $1.1 billion in revenues with all doses delivered by 1st half of 2022.
    About 95% of patients who took VIR-2218 plus PEG-IFN-a achieved Hepatitis B surface antigen ((HBsAg)) levels < 100 IU/mL.
    Expansion of pipeline moving towards the targeting of Hepatitis Delta Virus whereby both VIR-2218 and VIR-3434 will be tested against it.
    The global Hepatitis B Virus market is expected to reach $35.63 billion in 2030.
    Combination of VIR-2218 and VIR-3434 also being tested for the treatment of patients with Hepatitis B in a phase 2 study; results from this study expected by 2nd half of 2023.

StephenW

https://seekingalpha.com/article ... ommitments-expected